[go: up one dir, main page]

MX2009012957A - Method of treating diabetes. - Google Patents

Method of treating diabetes.

Info

Publication number
MX2009012957A
MX2009012957A MX2009012957A MX2009012957A MX2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A MX 2009012957 A MX2009012957 A MX 2009012957A
Authority
MX
Mexico
Prior art keywords
diabetic
treating diabetes
hbaic
hyperglycemia
worsening
Prior art date
Application number
MX2009012957A
Other languages
Spanish (es)
Inventor
Marcus Jerling
Andrew Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of MX2009012957A publication Critical patent/MX2009012957A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods are provided for lowering plasma level of HbAIc in a diabetic, pre- diabetic, or non-diabetic patient suffering from at least one cardiovascular disease and slowing or delaying the development of or worsening of hyperglycemia in a diabetic, pre-diabetic, or non-diabetic patient.
MX2009012957A 2007-05-31 2007-05-31 Method of treating diabetes. MX2009012957A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/070140 WO2008147417A1 (en) 2007-05-31 2007-05-31 Method of treating diabetes

Publications (1)

Publication Number Publication Date
MX2009012957A true MX2009012957A (en) 2010-03-03

Family

ID=38812044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012957A MX2009012957A (en) 2007-05-31 2007-05-31 Method of treating diabetes.

Country Status (11)

Country Link
EP (1) EP2152268A1 (en)
JP (1) JP2010528112A (en)
KR (1) KR20100038322A (en)
CN (1) CN101678017A (en)
AU (1) AU2007354300A1 (en)
BR (1) BRPI0721741A2 (en)
CA (1) CA2687381A1 (en)
IL (1) IL202002A0 (en)
MX (1) MX2009012957A (en)
NO (1) NO20093592L (en)
WO (1) WO2008147417A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
ES2523873T3 (en) 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor, such as ranolazine, for the treatment of diabetes
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
RU2691620C1 (en) * 2018-11-26 2019-06-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Method for prediction of the risk of developing ischemic heart disease in patients with type 2 diabetes mellitus combined with subclinical thyrotoxicosis
CN110812344A (en) * 2019-12-17 2020-02-21 卓和药业集团有限公司 Pharmaceutical composition for treating diabetes complicated with angina pectoris and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
ES2523873T3 (en) * 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor, such as ranolazine, for the treatment of diabetes
JP2008526879A (en) * 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド Sustained release pharmaceutical formulation containing ranolazine

Also Published As

Publication number Publication date
KR20100038322A (en) 2010-04-14
IL202002A0 (en) 2010-06-16
CA2687381A1 (en) 2008-12-04
WO2008147417A1 (en) 2008-12-04
BRPI0721741A2 (en) 2013-02-13
CN101678017A (en) 2010-03-24
AU2007354300A1 (en) 2008-12-04
NO20093592L (en) 2010-01-20
EP2152268A1 (en) 2010-02-17
JP2010528112A (en) 2010-08-19

Similar Documents

Publication Publication Date Title
MX2010001390A (en) Methods for treating dependence.
MX2010013876A (en) Aryl gpr119 agonists and uses thereof.
BRPI0822955A2 (en) method for operating an elevator in an emergency mode, and, elevator.
MX2009011359A (en) Pyrimidinone derivatives and methods of use thereof.
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
MX2009010899A (en) Predicting post-treatment survival in cancer patients with micrornas.
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
AU2010212865A8 (en) SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
WO2007124461A8 (en) Glp-1 compounds
ZA200901826B (en) Treating pain, diabetes, and lipid metabolism disorders
WO2010005982A3 (en) Multiplexed biomarkers of insulin resistance
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2008013863A3 (en) Generation of adipose tissue and adipocytes
WO2008084331A3 (en) Biomarkers for renal disorders
WO2009057119A3 (en) Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2
EP2203169A4 (en) Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
MX2009012957A (en) Method of treating diabetes.
WO2010124089A3 (en) Nepicastat for treating dependence
BR0311161A (en) Diabetes Treatment Method
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
IL192809A0 (en) Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients
PL2441462T3 (en) Method for treating type I diabetes
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GILEAD SCIENCES, INC.

FA Abandonment or withdrawal